Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

An Open Label Treatment Protocol to Provide Continued Elvucitabine Treatment

This study has been completed.
Sponsor:
Collaborators:
Bellos, Nicholaos C., M.D.
Central Texas Primary Care Research Network
Orlando Immunology Center
Saint Michael
Center for the Prevention and Treatment of Infections
Information provided by:
Achillion Pharmaceuticals
ClinicalTrials.gov Identifier:
NCT00675844
First received: May 8, 2008
Last updated: January 20, 2014
Last verified: January 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: March 2010
  Primary Completion Date: March 2010 (Final data collection date for primary outcome measure)
  Certification or Request for Extension to Delay Results Received: January 20, 2014